Join
Live feed
·
PRReleasevia Quantisnow
Nasus Pharma Ltd. logo

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

ByQuantisnow·Wall Street's wire, on your screen.
NSRX· Nasus Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NSRX (Nasus Pharma Ltd.) and more on Quantisnow.